Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Neuroinflammation may play a key role in the neurodegeneration associated with Parkinson's disease (PD). Non-steroidal anti-inflammatory drugs (NSAIDs) may be beneficial in the primary and secondary prevention of PD. OBJECTIVES: 1) Do NSAIDs prevent the onset of PD?2) Are NSAIDs neuroprotective in PD - do they slow the progression of disease once PD is established?3) What are the adverse effects of taking NSAIDs in PD? SEARCH METHODS: We searched electronic databases, including trial registers, complemented with handsearching of conference proceedings and citation searching on key articles. All searching was updated in May 2011. We contacted authors to provide additional information where necessary. SELECTION CRITERIA: For the primary prevention review, we sought primary prevention trials and observational studies (cohort and case-control studies). Participants were free of PD when exposure to NSAIDs was assessed. For the secondary prevention review, we sought clinical trials in patients with a well-defined definition of PD. Two people independently selected studies for inclusion using predetermined criteria. DATA COLLECTION AND ANALYSIS: Two review authors abstracted data from the source papers and assessed methodological quality independently. No studies met the inclusion criteria for the secondary prevention review. For the primary prevention review only observational studies were found. We combined data where appropriate using the inverse variance method. We assessed methodological quality using the Newcastle Ottawa Scales and by examining the period of exposure assessed prior to PD onset (or the index date in controls). MAIN RESULTS: Fourteen observational studies met the inclusion criteria for the primary prevention review (five cohort, nine case-control studies). Exposure to any NSAIDs or aspirin had no effect on the risk of developing PD. Exposure to non-aspirin NSAIDs reduced the risk of developing PD by 13% (effect estimate 0.87 (95% CI 0.73 to 1.04 - random-effects model), but this did not reach statistical significance. We found similar results for the most robust studies. Ibuprofen in isolation was examined in four studies and was associated with a 27% reduction in risk (effect estimate 0.73, 95% CI 0.63 to 0.85). There was a lack of information on adverse effects. AUTHORS' CONCLUSIONS: There is currently no evidence for the use of NSAIDs in the secondary prevention of PD. Non-aspirin NSAIDs, particularly ibuprofen, may reduce the risk of developing PD. However, little is known of the effects of other individual drugs and at present no recommendations can be made regarding their use in primary prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Szekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Research works printed but not linked: 44
- Bornebroek, 2007, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Neuroepidemiology, 28, 193, 10.1159/000108110 · DOI · Paper page
- Bower-JH, 2006, Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study, Neurology, 67, 494, 10.1212/01.wnl.0000227906.99570.cc · DOI · Paper page
- Chen, 2003, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Archives of Neurology, 60, 1059, 10.1001/archneur.60.8.1059 · DOI · Paper page
- Chen, 2005, Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease, Annals of Neurology, 58, 963, 10.1002/ana.20682 · DOI · Paper page
- Driver, 2011, Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case control study, British Medical Journal, 342, d198, 10.1136/bmj.d198 · DOI · Paper page
- Driver, 2011, Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case control study, British Medical Journal, 342, d198, 10.1136/bmj.d198 · DOI · Paper page
- Etminan, 2006, NSAID use and the risk of Parkinson's disease, Current Drug Safety, 1, 223, 10.2174/157488606777934404 · DOI
- Etminan, 2008, Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study, Journal of Clinical Neuroscience, 15, 576, 10.1016/j.jocn.2007.02.095 · DOI
- Gao, 2011, Use of ibuprofen and risk of Parkinson disease, Neurology, 76, 863, 10.1212/WNL.0b013e31820f2d79 · DOI · Paper page
- Hancock, 2007, Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease, Archives of Neurology, 64, 576, 10.1001/archneur.64.4.576 · DOI · Paper page
- Hernan, 2006, Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease, Neurology, 66, 1097, 10.1212/01.wnl.0000204446.82823.28 · DOI · Paper page
- Powers, 2008, Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk, Movement Disorders, 23, 88, 10.1002/mds.21782 · DOI · Paper page
- Ton, 2006, Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease, Movement Disorders, 21, 964, 10.1002/mds.20856 · DOI · Paper page
- Wahner, 2007, Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease, Neurology, 69, 1836, 10.1212/01.wnl.0000279519.99344.ad · DOI · Paper page
- Anderson, 1984, Diflunisal in idiopathic Parkinson's disease, Neurology, 34, 400, 10.1212/WNL.34.3.400 · doi:10.1212/wnl.34.3.400
- Chen, 2008, Peripheral inflammatory biomarkers and risk of Parkinson's disease, American Journal of Epidemiology, 167, 90, 10.1093/aje/kwm260 · DOI · Paper page
- Hakansson, 2007, Cycloxygenase-2 polymorphisms in Parkinson's disease, American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 144B, 367, 10.1002/ajmg.b.30449 · DOI
- Rugbjerg, 2010, Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study, Movement Disorders, 25, 2355, 10.1002/mds.23274 · DOI
- Wahner, 2007, Inflammatory cytokine gene polymorphisms and increased risk of Parkinson's disease, Archives of Neurology, 64, 836, 10.1001/archneur.64.6.836 · DOI · Paper page
- AD2000 Collaborative Group, 2008, Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial, Lancet Neurology, 7, 41, 10.1016/S1474-4422(07)70293-4 · DOI
- ADAPT research group, 2006, Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), PLoS Clinical Trials, 1, e33, 10.1371/journal.pctr.0010033 · DOI · Paper page
- Aisen, 2002, Randomized pilot study of nimesulide treatment in Alzheimer's disease, Neurology, 58, 1050, 10.1212/WNL.58.7.1050 · DOI · Paper page
- Asanuma, 2007, Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?, Experimental Neurology, 206, 172, 10.1016/j.expneurol.2007.05.006 · DOI
- Asanuma, 2008, Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease, Current Pharmaceutical Design, 14, 1428, 10.2174/138161208784480153 · DOI
- Breitner, 2009, Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort, Neurology, 72, 1899, 10.1212/WNL.0b013e3181a18691 · DOI · Paper page
- Reeves BC Deeks JJ Higgins JPT Wells GA Chapter 13: Including non-randomised studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org. · DOI · Paper page
- Davis, 2007, Aspirin and anti-inflammatory drugs for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006378 · DOI
- de-Craen, 2005, Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia, American Journal of Epidemiology, 161, 114, 10.1093/aje/kwi029 · DOI · Paper page
- Esposito, 2007, Non-steroidal anti-inflammatory drugs in Parkinson's disease, Experimental Neurology, 205, 295, 10.1016/j.expneurol.2007.02.008 · DOI · Paper page
- Klegeris, 2007, Therapeutic approaches to inflammation in neurodegenerative disease, Current Opinion in Neurology, 20, 351, 10.1097/WCO.0b013e3280adc943 · DOI · Paper page
- Konstantinopoulos, 2005, The cardiovascular toxicity of selective and nonselective cycloxygenase inhibitors: comparisons, contrasts and aspirin confounding, Journal of Clinical Pharmacology, 45, 742, 10.1177/0091270005278202 · DOI · Paper page
- Reines, 2004, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66 · DOI · Paper page
- The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008
- Salpeter, 2006, Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs, American Journal of Medicine, 119, 552, 10.1016/j.amjmed.2005.10.056 · DOI
- Sandyk, 1985, Acute exacerbation of Parkinson's disease with sulindac, Annals of Neurology, 17, 104, 10.1002/ana.410170124 · DOI
- Scharf, 1999, A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease, Neurology, 53, 197, 10.1212/WNL.53.1.197 · DOI · Paper page
- Shaunak, 1995, Exacerbation of idiopathic Parkinson's disease by naproxen, BMJ, 311, 422, 10.1136/bmj.311.7002.422b · doi:10.1136/bmj.311.7002.422b
- Smith, 2008, Inflammation in Parkinson's disease: an update, Current Opinion in Investigational Drugs, 9, 478
- Szekely, 2004, Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review, Neuroepidemiology, 23, 159, 10.1159/000078501 · DOI · Paper page
- Tabet, 2002, Indomethacin for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003673 · DOI · Paper page
- Tabet, 2003, Ibuprofen for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004031 · DOI
- Staa, 2008, What is the harm-benefit ratio of Cox-2 inhibitors?, International Journal of Epidemiology, 37, 405, 10.1093/ije/dym296 · DOI
- Wersinger, 2006, An inflammatory pathomechanism for Parkinson's disease?, Current Medicinal Chemistry, 13, 591, 10.2174/092986706776055760 · DOI · Paper page
- Whitton, 2007, Inflammation as a causative factor in the aetiology of Parkinson's disease, British Journal of Pharmacology, 150, 963, 10.1038/sj.bjp.0707167 · DOI · Paper page
Cited by
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., Chen, M., Sun, T., Xia, M., Ding, J., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596481 · Cited by 408
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“46, 52–58 37 Rees, K. et al. (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies.”
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228421 · Cited by 366
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Subramaniam, S. R., & Federoff, H. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00176 · Cited by 347
Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level
Gunaydin, C., & Bilge, S. S. (2019) · The Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2018.0010 · Cited by 284
The ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Immune aging, dysmetabolism, and inflammation in neurological diseases
Deleidi, M., Jäggle, M., & Rubino, G. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00172 · Cited by 260
“…anti-inflammatory drug (NSAID) treatment and lower incidence of AD and PD is still controversial (in t’ Veld et al., 2001; Chen et al., 2003; Wahner et al., 2007; Gao et al., 2011; Rees et al., 2011; Cote et al., 2012; Alzheimer’s Disease Anti-inflammatory Prevention Trial Research, 2013).”
BackgroundBiomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration
Azam, S., Haque, M. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683459 · Cited by 255
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., Sun, Y., Wu, J., Zhou, Q., Huang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719807 · Cited by 230
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229
“Observational evaluation of large cohorts of patients, suggests that the use of non-steroidal anti-inflammatory drugs reduces the risk of PD [193].”
BackgroundInflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175
“The implication of early involvement of immune system is also reinforced by epidemiological studies showing a prolonged use of NSAIDs (Nonsteroidal anti-inflammatory) particularly ibruprofen subsequently lowers the risk of PD (Rees et al., 2011).”
BackgroundSarkar, S., Rokad, D., Malovic, E., Luo, J., Harischandra, D. S., Jin, H., Anantharam, V., Huang, X., Lewis, M., Kanthasamy, A., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aat9900 · Cited by 171
“Use of anti-inflammatory drugs reduces the incidence of PD (11).”
BackgroundPeng, B., Yang, Q., B Joshi, R., Liu, Y., Akbar, M., Song, B.-J., Zhou, S., & Wang, X. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072316 · Cited by 156
The DNA Damage Response in Neurons: Die by Apoptosis or Survive in a Senescence-Like State?
Fielder, E., von Zglinicki, T., & Jurk, D. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161221 · Cited by 126
Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
Bassani, T. B., Vital, M. A. B. F., & Rauh, L. K. (2015) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20150057 · Cited by 78
Anti‐inflammatory treatment rescues memory deficits during aging in nfkb1−/− mice
Fielder, E., Tweedy, C., Wilson, C., Oakley, F., LeBeau, F. E. N., Passos, J. F., Mann, D. A., von Zglinicki, T., & Jurk, D. (2020) · Aging Cell · doi:10.1111/acel.13188 · Cited by 71
Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
Grimmig, B., Morganti, J., Nash, K., & Bickford, P. (2016) · Brain Sciences · doi:10.3390/brainsci6040041 · Cited by 17
Metadata
- Authors
- Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2011-11-09
- Volume
- 2011
- Issue
- 11
- Pages
- CD008454-CD008454
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2158835133
- Cited by
- 101
- References
- 9
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.